Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Physicians are Foregoing Treatment of Their HCV Patients Until New Agents Become Available

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that three-quarters of patients who have failed prior regimens, regardless of genotype, are not likely to re-treat their chronic hepatitis C virus (HCV) infection with a currently available regimen within the next year.

Published
06 August 2013
From
BioTrends
To End Hepatitis C, Patients Must Come Before Profits

The World Health Organization has dubbed hepatitis C, which infects as many as 185 million people worldwide, a "viral time bomb." On this World Hepatitis Day, July 28, it is important to know that this "bomb" can be defused if we can get companies to lower the price of treatment.

Published
30 July 2013
From
Huffington Post
Sign-on letter to Gilead about sofosbuvir

The TRT-5 and the CHV are requesting individual and organizational sign-ons to a letter urging Gilead to provide early access to sofosbuvir for people with the most urgent need.

Published
29 July 2013
From
TRT-5
Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C

FDA places partial clinical hold on ongoing Phase 2 U.S. study of VX-135, preventing evaluation of 200 mg dose following observation of elevated liver enzymes in patients receiving 400 mg of VX-135 in combination with ribavirin in Phase 2 study in Europe; evaluation of 100 mg dose continues in U.S.

Published
26 July 2013
From
Vertex press release
U.S. FDA puts hold on Vertex hepatitis study

Vertex Pharmaceuticals Inc said U.S. health regulators placed a partial clinical hold on a mid-stage study of an experimental oral hepatitis C treatment because of potential liver problems, sending its shares sharply lower on Thursday.

Published
26 July 2013
From
Reuters
Are Patients Receiving the Latest Anti-HCV Drugs?

Less than 20% of patients infected with the most common Hepatitis C virus (HCV) genotype receive the latest drugs approved by the US Food and Drug Administration (FDA), according to the August issue of Clinical Gastroenterology and Hepatology. This low percentage could result from concerns of side effects or patient hopes that more effective medications will soon become available.

Published
22 July 2013
From
AGA Journals blog
How to Save $200 Billion and Cure Hepatitis C

Price competition is going to play a bigger and bigger role in containing healthcare cost, and HCV treatment is one area where such competition won’t have to come at the expense of patient welfare.

Published
22 July 2013
From
Xconomy
TRT-5: Gilead refuses access to treatment to seriously ill hepatitis C patients

The French national regulation agency (Agence Nationale de Sécurité du Médicament, ANSM) has granted patient name-based temporary authorization of use (ATU) of sofosbuvir, a Gilead new compound, to people on the waiting list for a hepatic graft and to cirrhotic patients with no therapeutic option. Gilead Sciences Inc refuses to provide their new compound sofosbuvir.

Published
05 July 2013
From
EATG
AbbVie interferon-free hepatitis C combo works well with reduced ribavirin dose

People taking hepatitis C treatment who reduced their dose of ribavirin due to side-effects nevertheless had a high likelihood of achieving sustained virological response when treated with

Published
02 July 2013
By
Liz Highleyman
2013 Pipeline Report calls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible

HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

Published
30 June 2013
From
Treatment Action Group

Filter by country